Study of integrated protective immunity induced in rhesus macaques by the intradermal administration of a bivalent EV71-CA16 inactivated vaccine.
Enterovirus type 71 (EV71) and coxsackievirus A 16 (CA16) are recognized as the major pathogens responsible for human hand-foot-mouth disease. To develop a bivalent EV71-CA16 vaccine, rhesus macaques immunized with two doses of this vaccine via the intradermal route were challenged with EV71 or CA16, and their clinical symptoms, viral shedding, neutralizing antibodies, IFN-γ-specific ELISpots, and tissue viral load were examined longitudinally. Specific immunity against EV71 and CA16 was observed in the macaques, which exhibited controlled proliferation of the EV71 and CA16 viruses and upregulated expression of immune-related genes compared with the controls. Furthermore, broad protection against EV71 and CA16 challenge without immunopathological effects was observed in all the immunized macaques. These studies suggest that the bivalent EV71-CA16 inactivated vaccine was effective against wild-type EV71 or CA16 viral challenge in rhesus macaques.
['Fan|Shengtao|S|', 'Liao|Yun|Y|', 'Jiang|Guorun|G|', 'Jiang|Li|L|', 'Wang|Lichun|L|', 'Xu|Xingli|X|', 'Feng|Min|M|', 'Yang|Erxia|E|', 'Zhang|Ying|Y|', 'Cui|Wei|W|', 'Li|Qihan|Q|']
D000818:Animals D057134:Antibodies, Neutralizing D000914:Antibodies, Viral D004770:Enterovirus D029821:Enterovirus A, Human D006232:Hand, Foot and Mouth Disease D006801:Humans D000071497:Immunogenicity, Vaccine D008253:Macaca mulatta D017778:Vaccines, Combined D015164:Vaccines, Inactivated D014765:Viral Vaccines
Rhesus macaques Enterovirus type 71 (EV71) Coxsackievirus A 16 (CA16) Bivalent vaccine